HAEM5:Acute myeloid leukaemia with MECOM rearrangement - Revision history

Malini.Sathanoori at 10:57, 9 September 2025

2025-09-09T10:57:40Z

← Older revision		Revision as of 05:57, 9 September 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute myeloid leukaemia with MECOM rearrangement}}		{{DISPLAYTITLE:Acute myeloid leukaemia with MECOM rearrangement}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

Jennelleh: /* Gene Rearrangements */

2025-09-08T19:29:02Z

Gene Rearrangements

← Older revision		Revision as of 14:29, 8 September 2025
Line 50:		Line 50:

	[[File:inv(3)(q21q26.2).png\|inv(3)(q21q26.2)]][[File:t(3;3)(q21;q26.2).png\|t(3;3)(q21;q26.2)]]		[[File:inv(3)(q21q26.2).png\|inv(3)(q21q26.2)]][[File:t(3;3)(q21;q26.2).png\|t(3;3)(q21;q26.2)]]

	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"

Jennelleh at 19:28, 8 September 2025

2025-09-08T19:28:43Z

← Older revision		Revision as of 14:28, 8 September 2025
Line 13:		Line 13:

	Gordana Raca MD PhD, University of Southern California, Los Angeles		Gordana Raca MD PhD, University of Southern California, Los Angeles
	~~[[File:inv(3)(q21q26.2).png\|inv(3)(q21q26.2)]]~~
	~~[[File:t(3;3)(q21;q26.2).png\|t(3;3)(q21;q26.2)]]~~

	==WHO Classification of Disease==		==WHO Classification of Disease==
Line 51:		Line 49:
	==Gene Rearrangements==		==Gene Rearrangements==

			[[File:inv(3)(q21q26.2).png\|inv(3)(q21q26.2)]][[File:t(3;3)(q21;q26.2).png\|t(3;3)(q21;q26.2)]]
	Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>		Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"

Malini.Sathanoori at 20:10, 7 September 2025

2025-09-07T20:10:02Z

← Older revision		Revision as of 15:10, 7 September 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute myeloid leukaemia with MECOM rearrangement}}		{{DISPLAYTITLE:Acute myeloid leukaemia with MECOM rearrangement}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 388:		Line 389:
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

			Prior Author(s):

Bailey.Glen at 17:07, 3 July 2025

2025-07-03T17:07:11Z

← Older revision		Revision as of 12:07, 3 July 2025
Line 37:		Line 37:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:26, 25 May 2025

2025-05-25T21:26:35Z

← Older revision		Revision as of 16:26, 25 May 2025
Line 150:		Line 150:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 215:		Line 215:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 261:		Line 261:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:02, 25 May 2025

2025-05-25T20:02:59Z

← Older revision		Revision as of 15:02, 25 May 2025
Line 52:		Line 52:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Acute myeloid leukaemia with EVI1 rearrangement
	\|}		\|}

Bailey.Glen at 17:30, 24 March 2025

2025-03-24T17:30:34Z

← Older revision		Revision as of 12:30, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute myeloid leukaemia with MECOM rearrangement}}		{{DISPLAYTITLE:Acute myeloid leukaemia with MECOM rearrangement}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Gordana Raca MD PhD, University of Southern California, Los Angeles		Gordana Raca MD PhD, University of Southern California, Los Angeles

	~~__TOC__~~

	[[File:inv(3)(q21q26.2).png\|inv(3)(q21q26.2)]]		[[File:inv(3)(q21q26.2).png\|inv(3)(q21q26.2)]]
	[[File:t(3;3)(q21;q26.2).png\|t(3;3)(q21;q26.2)]]		[[File:t(3;3)(q21;q26.2).png\|t(3;3)(q21;q26.2)]]

Bailey.Glen: Removed old template contents

2025-02-11T13:45:29Z

Removed old template contents

Show changes

Bailey.Glen at 18:38, 10 February 2025

2025-02-10T18:38:09Z

Show changes